Dave Fellows, Beacon Therapeutics CEO

Bea­con rais­es $170M to take on J&J in oc­u­lar gene ther­a­py

Transat­lantic biotech Bea­con Ther­a­peu­tics has raised $170 mil­lion to po­ten­tial­ly bring a rare oph­thal­mol­o­gy gene ther­a­py to mar­ket in a com­pe­ti­tion with John­son & John­son …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.